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Abstract
Background: Chlamydia trachomatis is the causative agent of the most common bacterial sexually transmitted infection
worldwide. The aim of this study was to investigate the frequency and genotypes of C. trachomatis in patients attending
an obstetrics and gynecology clinic in Jalisco, Mexico and correlates them with sociodemographic, behavioral, and
biological factors.
Methods: C. trachomatis detection was performed in endocervical samples from 662 patients by direct fluorescence
assay (DFA) and two PCR assays that amplified the phospholipase D endonuclease superfamily protein (PLDESP) and
OmpA genes. Positive samples were genotyped using PCR–restriction fragment length polymorphism assays.
Sociodemographic, behavioral, and biological data were collected.
Results: The mean age of the study population was 31 (range, 14–78) years. C. trachomatis positivity was detected by
DFA in 16.7% (n = 111), PLDESP gene amplification in 14.2% (n = 94), and OmpA gene amplification in 14.5% (n = 96) of
the population. Eight C. trachomatis genotypes were detected: E (39.6%), F (29.2%), D (15.6%), K (6.3%), L2 (3.1%), G, J, and
I (2.1% each). C. trachomatis infection was associated with age, marital status, pregnancy, and hormonal contraceptive use
(all p = 0.01); intrauterine device use and previous premature birth (both p = 0.03); and infection during pregnancy,
previous ectopic pregnancy, pelvic inflammatory disease (PID), and green vaginal discharge (all p = 0.04). C. trachomatis
genotype K was more likely to be detected in women histories of ≥2 sexual partners, genotype F was more likely in
pregnant women, genotype L2 was more likely in women with PID, genotype D was more likely in women who had had
infection during previous pregnancies, and genotype E was more likely in those with previous ectopic pregnancies and
green vaginal discharge (all p = 0.01).
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Conclusions: The frequency of C. trachomatis in our population was higher than previously reported
worldwide, but within the range reported for Mexico. Genotype E was detected most frequently in the study
population. Infection by C. trachomatis and C. trachomatis genotypes K, F, D, and E was strongly associated
with multiple sociodemographic, behavioral, and biological factors. C. trachomatis genotype L2 was detected
in women with PID.
Keywords: Chlamydia trachomatis, Genotype, Pregnancy, Mexico, Lymphogranuloma venereum
Background
Chlamydia trachomatis is the causative agent of the most
common bacterial sexually transmitted infection (STI)
worldwide [1], and the most frequently reported of all
notifiable infections in the United States and Europe. In
the United States alone, an estimated 2 – 5 million new
cases of C. trachomatis infection occur each year [2, 3].
The infection is asymptomatic in almost 80% of women,
and untreated genital infections lead to serious compli-
cations, such as pelvic inflammatory disease (PID) and
infertility [4]. Asymptomatic infected people not only
are at risk of developing serious long-term sequelae, but
also transmit the infection. In these individuals, diagno-
sis of C. trachomatis infection is difficult because the
pathogen load is low [5].
Nucleic acid amplification tests are the preferred
method for the diagnosis of C. trachomatis genital in-
fection because of their high sensitivity and specificity
[4]. C. trachomatis typing is based on assays of the
major outer membrane protein (MOMP). This ana-
lysis differentiates 18 genotypes based on changes in
the single copy of the OmpA gene, which encodes the
MOMP [6]. Genotypes A to C are associated with
trachoma, genotypes D to K are associated with com-
mon urogenital and ocular pathogens in adults, and
genotypes L1 to L3 are associated with lymphogranu-
loma venereum (LGV). In developed countries, geno-
types D, E, and F are most commonly associated with
genital infections [7–9].
Previous studies have documented C. trachomatis fre-
quencies ranging from 1.5 to 28% in female populations
in Mexico [10, 11]. The only Mexican study that has in-
cluded reporting on C. trachomatis genotypes showed
that 24 of 152 (15.8%) infertile patients were positive for
C. trachomatis, and that the most prevalent genotype
was F [12]. Thus, additional studies describing the fre-
quency and genetic distribution of C. trachomatis in
Mexico are needed. The aim of this study was to investi-
gate the frequency and genotypes of C. trachomatis in
patients attending the obstetrics and gynecology clinic of
the Fray Antonio Alcalde Civil Hospital in Jalisco,
Mexico and correlates them with Sociodemographic, be-
havioral, and biological factors.
Methods
Ethics statement
This study was performed with the approval of the Local
Ethics Committee of the Hospital Civil de Guadalajara
“Fray Antonio Alcalde” in Jalisco, Mexico (approval no.
062/13). Written informed consent was obtained from
all patients or, for minors, from caretakers or guardians.
Study population and data collection
This was a cross-sectional study, conducted in the obstet-
rics and gynecology department of the Hospital Civil de
Guadalajara “Fray Antonio Alcalde” from September 2013
to August 2014. Only patients attending the clinic for the
first time were invited to participate. Sociodemographic
and clinical data were collected for each patient.
Specimen collection and DNA isolation
Endocervical samples were collected using two sterile
Dacron-tipped swabs and placed in 2-sucrose phosphate
medium. Tubes were stored at −20 °C until analyzed.
To obtain C. trachomatis DNA, one swab was subjected
to enzymatic lysis with lysozyme and proteinase K.
Genomic DNA was extracted using a standard phenol-
chloroform-isoamyl alcohol protocol. The concentration
and purity of the extracted DNA was evaluated through a
spectrophotometer (GENESYS™ 20, Thermo Fisher
Scientific, Germany).
Direct fluorescence assay
C. trachomatis was detected by direct fluorescence assay
(DFA) using a monoclonal anti-Chlamydia antibody
(BioMérieux, France). The endocervical samples were
transferred to clean slides, which were incubated with
fluorescent monoclonal antibody for 30 min at a
controlled temperature of 25 °C. The samples were ob-
served under a fluorescence microscope (Axio Scope.A1;
Zeiss, NY). Positive and negative controls were included
in all assays.
Phospholipase D Endonuclease Superfamily protein gene
analysis
Polymerase chain reaction (PCR) assays were performed
to amplify the phospholipase D endonuclease superfamily
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(PLDESP) gene using the method described by Gimenes
et al. [13] and amplify a fragment of 361 bp for about
60 min. The total volume was 25 μL, consisting of 2.5 μL
10× PCR buffer, 100 ng DNA, 3 mM MgCl2, 200 μM of
each deoxynucleotide triphosphate (dNTP), and 1 U Taq
polymerase (Bioline, London, UK). The primers used were
CT-F (5′-TCTTTTTAAACCTCCGGAACCCACTT-3′)
and CT-R (5′-GGATGGCATCGCATAGCATTCTTTG-
3′). Each run was accompanied by positive and negative
control sample. The thermocycler conditions were: 3 min
at 94 °C; then 35 cycles of 30 s at 94 °C, 30 s at 50 °C, and
30 s at 72 °C; and a final extension of 5 min at 72 °C. The
amplification products were visualized using electrophor-
esis on a 2.5% agarose gel stained with 1 μg/mL ethidium
bromide, and compared with a standard (DNA Molecular
Weight, Marker 100, Sigma Aldrich, St. Louis, MO, USA),
and developed with a UV transilluminator (UVP BioIma-
ging Systems Photodocumentator, Upland, CA).
OmpA gene analysis and restriction fragment length
polymorphism analysis
The OmpA gene of C. trachomatis was amplified using
the method described by Lan et al. [14] with small modi-
fications, to amplify a fragment of 1100 bp The total vol-
ume was 25 μL, consisting of 2.5 μL 10× PCR buffer,
100 ng DNA, 3 mM MgCl2, 200 μM of each dNTP, and
1 U Taq polymerase (Bioline). The primers used were
SERO1A (5′-ATGAAAAAACTCTTGAAATCGG-3′)
and SERO2A (5′-TTT CTA GAT CTT CAT TCT TGT
T-3′). Each run was accompanied by positive and nega-
tive control sample. The thermocycler conditions were:
7 min at 94 °C; then 40 cycles of 3 min at 95 °C, 3 min
at 45 °C, and 3 min at 72 °C; and a final extension of
7 min at 72 °C. The amplification products were visual-
ized using electrophoresis on a 1.5% agarose gel stained
with 1 μg/mL ethidium bromide, and compared with a
standard (DNA Molecular Weight, Marker 1000, Sigma
Aldrich, St. Louis, MO, USA), and developed with a UV
transilluminator (UVP BioImaging Systems Photodocu-
mentator, Upland, CA). Then, 0.5 μl of the first-round
PCR product was used for semi-nested PCR, which was
performed with the same reagents and conditions except
for the primers. The primers used for this assay were
SERO2A and the nested primer PCTM3 (5′-
TCCTTGCAAGCTCTGCCTGTGGGGAATCCT-3′).
The PCR products of the second round were analyzed
using electrophoresis on a 1.5% agarose gel stained with
1 μg/mL ethidium bromide, and compared with a stand-
ard (DNA Molecular Weight, Marker 1000, Sigma Al-
drich, St. Louis, MO, USA), and developed with a UV
transilluminator (UVP BioImaging Systems Photodocu-
mentator, Upland, CA). Positive samples were genotyped
by PCR–restriction fragment length polymorphism
(RFLP) assays, as described by Sayada et al. [15], using
1000-bp semi-nested PCR products. The nested PCR
product (10 μL) was digested with 2.5 U Alu I (Promega,
Madison, WI, USA) overnight at 37 °C. Depending on
the patterns obtained, the products were digested with
the enzyme Hinf I (Promega). Genotypes were identified
by their restriction patterns on ethidium bromide–
stained 3.5% agarose gels. We used control DNA from
the C. trachomatis strain ATCC VR-902B MOMP gene,
partial cds (AmpliRun, ref. MBC012).
Statistical analysis
Descriptive analysis was performed. We used the
Wilcoxon rank-sum test to compare mean values and
Fisher’s exact test or the chi-squared test to compare di-
chotomous variables. Analyses were performed using
SPSS (version 18).
Results
Study population and patient characteristics
Of 30,000 female patients estimated who visited the ob-
stetrics and gynecology department, 662 patients were
enrolled in this study. Only patients who agreed to par-
ticipate and were attending the clinic for the first time
were included. The mean age of the study population
was 31 (range, 14–78) years. The largest proportion
(38.5%, n = 255) of patients was aged 20–29 years. Most
(75.5%, n = 500) patients were married or living with a
partner, and 37.6% (n = 249) reported using condoms as
a contraceptive method. The majority (69.5%, n = 460)
of patients were housewives, and 43.3% (n = 287) were
pregnant at the time of sample collection (Table 1).
Detection of infection
C. trachomatis positivity was detected by DFA in 16.7%
(n = 111) of the study population, by PLDESP gene amp-
lification in 14.2% (n = 94), and by OmpA gene amplifi-
cation in 14.5% (n = 96) of the population. According to
PCR-RFLP results, the most frequent OmpA genotype
corresponded to E (39.6%, n = 38), followed by F (29.2%,
n = 28), D (15.6%, n = 15), K (6.3%, n = 6), and L2
(3.1%, n = 3). Genotypes G, I, and J were detected less
frequently (2.1%, n = 2 each; Table 2). Final results were
regarded as true positives if the semi-nested PCR was
positive (gold standard). The overall agreement of DFA
results with semi-nested PCR the validation parameters
were as follows: sensitivity 96%, specificity 97.3%, nega-
tive predictive value 99.3%, positive predictive value
86.5%, and accuracy 97.3%. Comparing the PCR results
of the PLDESP gene with semi-nested PCR the valid-
ation parameters were as follows: sensitivity 98.6%, spe-
cificity 100%, negative predictive value 99.6%, positive
predictive value 100%, and accuracy 99.7%.
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Table 1 Associations of C. trachomatis with sociodemographic, behavioral, biological factors and specific symptoms of the study
population
Characteristic Total positive population
[n (%), n = 662]
C. trachomatis positive by OmpA
[n (%), n = 96]
P Adjusted OR
(95% CI)
SOCIODEMOGRAPHIC FACTORS
Age group (years)
14–19 93 (14) 10 (10.4) 0.14 0.68 (0.32, 1.33)
20–29 255 (38.5) 35 (36.5) 0.32 0.90 (0.57, 1.41)
30–39 186 (28.1) 23 (24) 0.16 0.77 (0.46, 1.27)
≥ 40 129 (19.5) 28 (29.2) 0.01 2.69 (1.61, 4.44)
Occupation
Housewife 460 (69.5) 64 (66.7) 0.26 0.85 (0.53, 1.32)
Employee/merchant 106 (16) 19 (19.8) 0.13 1.37 (0.77, 2.36)
Professional 63 (9.5) 8 (8.3) 0.34 0.84 (0.36, 1.77)
Student 33 (5) 5 (5.2) 0.43 1.05 (0.35, 2.66)
Marital status
Single 140 (21.2) 4 (4.2) 0.43 1.05 (0.32, 2.61)
Divorced/widowed/separated 22 (3.3) 8 (8.3) 0.34 0.84 (0.36, 1.77)
Married/living with partner 500 (75.5) 83 (86.5) 0.01 1.99 (1.10, 3.83)
BEHAVIORAL FACTORS
Alcohol use 145 (21.9) 23 (24) 0.31 1.12 (0.69, 1.77)
Current smoker 200 (30.21) 31 (32.3) 0.29 1.14 (0.67, 1.89)
Age at first intercourse (years)
< 18 330 (49.9) 47 (49) 0.43 0.96 (0.62, 1.49)
≥ 18 332 (50.2) 49 (51) 0.17 1.23 (0.79, 1.91)
No. of sex partners
0 7 (1) 2 (2.1) 0.16 2.38 (0.31,12.27)
1 311 (47) 40 (41.7) 0.13 0.77 (0.49, 1.20)
2–4 279 (42.2) 43 (44.8) 0.28 1.13 (0.73, 1.75)
≥ 5 65 (9.8) 11 (11.5) 0.27 1.22 (0.59, 2.38)
Contraceptive use
Hormonal 102 (15.4) 7 (7.3) 0.01 0.39 (0.16,0.38)
Condom 249 (37.6) 39 (40.6) 0.25 1.16 (0.74, 1.82)
IUD 67 (10.1) 15 (15.6) 0.03 1.79 (0.93, 3.28)
Bilateral tubal occlusion 40 (6) 5 (5.2) 0.37 0.83 (0.28, 2.06)
None 204 (30.8) 39 (40.6) 0.02 1.55 (0.99, 2.42)
BIOLOGICAL FACTORS
Pregnant at sampling 287 (43.3) 31 (32.3) 0.01 0.57 (0.36, 0.91)
Previous pregnancy 621 (93.8) 88 (91.7) 0.19 0.70 (0.32, 1.67)
Complications of previous pregnancy
Infection 386 (58.3) 49 (51) 0.04 0.69 (0.44, 1.07)
Bleeding 69 (10.4) 10 (10.4) 0.48 0.99 (0.46, 1.97)
Risk of spontaneous abortion 116 (17.5) 15 (15.6) 0.31 0.85 (0.45, 1.51)
Premature birth 50 (7.5) 12 (12.5) 0.03 1.98 (0.96, 3.88)
Ectopic pregnancy 9 (1.35) 4 (4.1) 0.03 3.46 (0.87,12.19)
Previous abortion 163 (24.6) 26 (27.1) 0.25 1.17 (0.71, 1.90)
SPECIFIC SYMPTOMS
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Association of C. trachomatis infection with
sociodemographic, behavioral, biological factors, and
specific symptoms
C. trachomatis infection was associated with age ≥ 40 years,
being married or living with a partner, and the use of
hormonal contraceptives (all p = 0.01), as well as intra-
uterine device (IUD) use (p = 0.03) and no history of
birth control use (p = 0.02). In addition, pregnant
women (p = 0.01) and those who had had infections dur-
ing pregnancy (p = 0.04) were more likely to be infected.
Infected women were more likely to have previous his-
tories of giving birth prematurely (p = 0.03), ectopic
pregnancy, PID, or green vaginal discharge (all p = 0.04;
Table 1).
Association of C. trachomatis genotypes with risk factors,
and specific symptoms
Women with histories of two or more sexual partners
were more likely to be infected with C. trachomatis
genotype K (p = 0.01), whereas pregnant women were
more likely to be infected with C. trachomatis genotype
F (p = 0.03). Associations were detected between geno-
type F, L2 is associated with PID (p = 0.02), genotype D
and infection during previous pregnancy (p = 0.02), and
genotype E was associated with previous ectopic preg-
nancy (p = 0.04) and green vaginal discharge (p = 001;
Table 2). We found no association of any C. trachomatis
genotype with previous pregnancy, abortion, premature
birth and specific symptoms (data not shown).
Discussion
C. trachomatis is a causal factor of STI, the course of
which is frequently asymptomatic. In this study, the
frequency and genotypes of C. trachomatis in patients
attending a gynecology clinic in the largest public hos-
pital in the state of Jalisco were determined. To our
knowledge, this work is the largest molecular epidemio-
logical study of C. trachomatis frequency and genotypes
in Mexico, and their associations with sociodemo-
graphic, behavioral, and biological factors.
The frequency of C. trachomatis detected by PCR in
this study was 14.5%. Previous studies in Mexican popu-
lations have detected C. trachomatis at frequencies ran-
ging from 1.5% to 28% [10, 11]. Our results thus fall
within the reported range for Mexico. The frequency de-
tected in the current study was higher than reported for
Australia (4.9%) [16, 17], Spain (4%) [17], France (3.6%)
[18], and the United Kingdom (3%) [19].
Current guidelines from the Centers for Disease
Control and Infection recommend annual screening for
this bacteria in sexually active women aged ≤ 25 years
and in those aged >25 years who are at risk of infection
[20]. In Mexico, C. trachomatis infection is not a notifi-
able disease; thus, routine testing is not mandatory. This
situation makes the collection of reliable epidemiological
data from throughout the country difficult.
The prevalence of C. trachomatis genotypes has been
determined for several countries, but little such data are
available for Latin America. In our study, the most fre-
quent genotype was E (39.6%), followed by F (29.2%)
Table 1 Associations of C. trachomatis with sociodemographic, behavioral, biological factors and specific symptoms of the study
population (Continued)
PID 295 (44.5) 36 (37.5) 0.04 0.68 (0.32, 1.33)
Dyspareunia
Pain /burning 222 (33.5) 27 (28.1) 0.11 0.74 (0.45, 1.19)
Bleeding 28 (4.2) 3 (3.1%) 0.3 0.69 (0.16, 2.14)
Vaginal discharge
Amount
Scarce 101 (15.2) 16 (16.7) 0.33 1.13 (0.61, 2.00)
Moderate 322 (48.6) 44 (45.8) 0.27 0.87 (0.56, 1.35)
Copious 185 (27.9) 26 (27.1) 0.42 0.95 (0.57, 1.53)
Color
White 450 (68) 65 (67.7) 0.47 0.98 (0.62, 1.58)
Yellow 194 (29.3) 24 (25) 0.15 0.77 (0.46, 1.27)
Green 45 (6.8) 11 (11.5) 0.04 1.90 (0.89, 3.81)
Brown 19 (2.8) 5 (5.2) 0.47 0.98 (0.62, 1.58)
Previous infection
Urinary 188 (28.4) 23 (24) 0.14 0.76 (0.45, 1.25)
Vaginal 420 (63.4) 58 (60.4) 0.25 0.86 (0.55, 1.34)
OR odds ratio, CI confidence interval, IUD Intrauterine Device, PID pelvic inflammatory disease
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and D (15.6%). In a previous study of C. trachomatis in
Mexico, genotype F was most frequent (54.2%), followed
by genotypes E, G, K, and L2 (8.7% each); genotypes D,
F, and I were detected at a frequency of 4.2% each [12].
That study, however, involved the examination of only
152 samples from infertile women (with only 24 speci-
mens positive for C trachomatis), and limited clinical
data were reported that contrasted with our results, this
may be due to the small sample analyzed by the previous
study [12]. Our results are similar to those reported
from other Latin America and other parts of the world.
In a Brazilian study that included 141 women, the most
frequent genotype detected was E (39.7%), followed by F
(17.7%) and D (17%) [21]. In a Costa Rican study includ-
ing 806 C. trachomatis–positive samples, genotype E
was also most frequent (31%), followed by F and D (21%
each) [22]. Genotype E was most frequent in a study in-
cluding 81 women conducted in Argentina [23]. Similar
frequencies have been reported in other parts of the
world, including the Netherlands (E, 41.5%; F, 21.8%; D,
11.9%) [24], China (E, 37.2%; F, 31.3%) [25], and Alabama,
United States (E, 29%; F and D, 19% each) [26].
In our population, genotype L2 was identified in three
patients with no clinical data of LGV. This situation has
been described previously in Mexico [12]. LGV is a
sexually transmitted disease caused by C. trachomatis se-
rotypes L1, L2, and L3. It probably affects both sexes
equally, although it has been reported more frequently
in men, in whom the early manifestations of the disease
are more evident. Men often display the acute form of
LGV, whereas it is often detected in women when late-
stage complications develop [27]. Most cases in Europe
and North America have been identified in men who
have sex with men [28]. A small number of genotype L
cases has been reported in heterosexuals in the United
Kingdom and Europe, including seven women in the UK
since 2004, but these cases appear to be linked to male
bisexual partners or sexual contact with those returning
from endemic areas [29].
Interestingly, patients who were married or living with
a partner were most at risk of infection with C. tracho-
matis in the present study. This finding may be
explained by the lack of contraceptive use or infection
prevention in this population.
An association of hormonal contraceptive use with the
risk of infection was detected in the present study, con-
firming the results of previous studies [30]. Hormonal
contraception is associated with an increased rate of
cervical colonization because estrogen supports bacterial
growth [31].
Recent studies have shown that IUD use is safe for all
women, including those at high risk of STIs [32]. In this
study, patients using IUDs were more likely to be in-
fected with C. trachomatis than were those who did not
report IUD use, possibly due to the trauma caused by
IUDs.
Of special concern is the strong association between
C. trachomatis infection and pregnancy at the time of
sampling. Prompt diagnosis in this population is a
cornerstone for the prevention of infection in new-
borns [33].
In the current study, C. trachomatis infection was as-
sociated with PID. Several studies have demonstrated
that women who test positive for C. trachomatis have an
increased risk of PID throughout their reproductive life
compared with women who test negative [34, 35]. PID
has also been suggested to be associated with an in-
creased risk of repeated infection [36].
Possible associations of C. trachomatis genotypes with
specific clinical symptoms or the pathogenicity of the
disease have not been described completely. In a previ-
ous study, C. trachomatis genotype K was associated
with vaginal discharge [37]; in our sample, genotype K
was detected more frequently in patients with multiple
partners. Furthermore, genotype F was detected more
frequently in pregnant women. C. trachomatis genotype
F has been associated with reduced mucopurulent endo-
cervical discharge [38] and inflammation in men, but
not in women [39]. Women who reported abdominal
pain were more likely to be infected with genotype F
[40]. In this study, genotype E was associated with previ-
ous ectopic pregnancy and green vaginal discharge. In a
previous study, genotype E was associated with conjunc-
tivitis in neonates [23].
Conclusion
To our knowledge, this study is the only molecular
epidemiological research to date on the frequency and
genotypes of C. trachomatis, and their associations
with sociodemographic, behavioral, and biological fac-
tors, in women attending a gynecology and obstetrics
clinic in Mexico. This is a preliminary report and
should be done in a much larger cohort, with a
greater number of positive samples for Chlamydia.
The frequency of C. trachomatis in our population
was higher than previously reported worldwide, but
within the range reported for Mexico. Genotype E
was detected most frequent in the study population.
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